NEW YORK, Feb. 09, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Jason Slakter, Chief Executive Officer, will present a corporate overview and business update at the Leerink Global Healthcare Conference at the Waldorf Astoria in New York, NY.
Details of the Presentations:
Date: Thursday, February 11
Time: 10:45am Eastern
Room: Carnegie Suite
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) is an ophthalmology research and development company. The company's lead product, OHR-102 (Squalamine Lactate Ophthalmic Solution, 0.2%), is currently being studied as an eye drop formulation in clinical trials for back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. Additional information on the company may be found at www.ohrpharmaceutical.com.
Contact: Ohr Pharmaceutical Inc. Investor Relations 888-388-2327 email@example.com LifeSci Advisors, LLC Michael Wood 646-597-6983 firstname.lastname@example.org